Overview

Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients

Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are: 1. To evaluate the effect of OT compared to placebo, as add-on to anti-psychotics, on social functioning in schizophrenia. 2. To evaluate the effect of socially oriented CBT administered to patients immediately after they receive OT, compared to patients who receive OT with not-socially oriented CBT, and compared to patients who receive socially oriented CBT without OT. The investigators hypothesize that OT and socially oriented CBT will have a synergistic effect, and will be better than OT or CBT alone. 3. Use a detailed, in depth analysis of social interaction to assess these putative effects of OT. The investigators hypothesize that the use of this analysis will show larger treatment effects of OT than previously shown in less sensitive assessments, such as PANSS. 4. To assess the effect of epigenetic status on response to OT. The investigators hypothesize that epigenetic variants associated with lower OT plasma levels will be associated with greater response to OT treatment. 5. To assess in the relationships between levels of salivary OT and vasopressin, and social interactions in schizophrenia. 6. To assess in the relationships between levels of salivary OT and vasopressin, and response to OT treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Sheba Medical Center
Treatments:
Oxytocin